| DESCRIPTION OF ENHANCEMENTS |
The released patch PSS*1*219 provided functionality to exclude
buccal film.
buprenorphine-containing products from requiring an X-number (Detox
Number) when they are specifically FDA approved with indication for the
treatment of pain. This was done by dosage form so that Butrans (patch)
and Belbuca (film, buccal), the products available at the time, could be
excluded. However, a new product, Bunavail has been released to market.
This is also a buccal film but is primarily indicated for treatment of
opioid substance use disorder. Therefore, changes are needed that will
require an X-number when a Bunavail order is placed with a dosage form of
|
